Friday, 9 May 2025
  
Login

Australia's most trusted
source of pharma news

Friday, 09 May 2025
News

Amgen's $42B play pays off

Posted 17 March 2025 AM 

Last week the TGA approved Amgen’s monoclonal antibody Uplizna - the first drug to come out of the pharma’s AUD$42 billion acquisition of Dublin-based Horizon Therapeutics.

Uplizna is indicated as monotherapy for the treatment of adults with neuromyelitis optica spectrum disorder who are anti-aquaporin-4 immunoglobulin G seropositive.

To see the whole article, please login

Popular

What downturn? Pharma is back
How leaders can fix disengagement
Who's industry's 'Most Influential'?
Drug flood overwhelming HCPs
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2025 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home